NasdaqGM - Nasdaq Real Time Price USD

ARS Pharmaceuticals, Inc. (SPRY)

12.18
+0.08
+(0.66%)
As of 10:17:05 AM EDT. Market Open.
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Total Revenue
89,149
89,149
30
1,316
5,506
Cost of Revenue
977
977
0
--
--
Gross Profit
88,172
88,172
30
--
--
Operating Expense
91,255
91,255
67,550
36,832
24,960
Operating Income
-3,083
-3,083
-67,520
-35,516
-19,454
Other Income Expense
11,369
11,369
13,155
834
-789
Pretax Income
8,286
8,286
-54,365
-34,682
-20,243
Tax Provision
288
288
0
--
--
Net Income Common Stockholders
7,998
7,998
-54,365
-34,682
-20,243
Diluted NI Available to Com Stockholders
7,998
7,998
-54,365
-34,682
-20,243
Basic EPS
0.08
--
-0.57
-0.87
-0.22
Diluted EPS
0.08
--
-0.57
-0.87
-0.22
Basic Average Shares
96,936.66
--
95,215.32
39,956.04
93,770.17
Diluted Average Shares
102,390.83
--
95,215.32
39,956.04
93,770.17
Total Operating Income as Reported
-3,083
-3,083
-67,520
-35,516
-19,454
Total Expenses
92,232
92,232
67,550
36,832
24,960
Net Income from Continuing & Discontinued Operation
7,998
7,998
-54,365
-34,682
-20,243
Normalized Income
7,998
7,998
-54,365
-34,542
-20,243
EBIT
-3,083
-3,083
-67,520
-35,516
-19,454
EBITDA
-3,083
-3,083
-67,520
-35,197
-19,241
Reconciled Cost of Revenue
977
977
0
--
--
Reconciled Depreciation
-7,175
-7,175
-6,775
319
213
Net Income from Continuing Operation Net Minority Interest
7,998
7,998
-54,365
-34,682
-20,243
Total Unusual Items Excluding Goodwill
--
--
--
-140
--
Total Unusual Items
--
--
--
-140
--
Normalized EBITDA
-3,083
-3,083
-67,520
-35,057
-19,241
Tax Rate for Calcs
0
0
0
0
0
Tax Effect of Unusual Items
0
0
0
0
0
12/31/2021 - 12/4/2020

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

SRRK Scholar Rock Holding Corporation
30.07
-1.56%
 
ARQT Arcutis Biotherapeutics, Inc.
13.36
-1.76%
 
AKRO Akero Therapeutics, Inc.
37.92
+0.11%
 
SCPH scPharmaceuticals Inc.
2.5200
+12.50%
 
VRNA Verona Pharma plc
67.49
+0.36%
 
ASND Ascendis Pharma A/S
155.14
-1.31%
 
CRNX Crinetics Pharmaceuticals, Inc.
30.73
-1.81%
 
URGN UroGen Pharma Ltd.
9.69
-1.87%
 
RCKT Rocket Pharmaceuticals, Inc.
5.81
-4.07%
 
RGNX REGENXBIO Inc.
7.87
-5.52%